Multiple myeloma genetic discovery promises better treatment:
This article was originally published in Clinica
US researchers have categorised four distinguishing gene patterns for the blood cancer multiple myeloma, which could allow doctors to better predict how patients will respond to current treatments. The team, which included collaborators from the Dana-Farber Cancer Institute in Boston, Massachusetts, said that patients with each gene pattern can be correlated with different clinical outcomes. The findings could lead to the design of drugs targeted at these specific gene patterns. The results appear in the April issue of Cancer Cell. Mutiple myeloma is the second most common form of blood cancer after non-Hodgkin's lymphoma.
You may also be interested in...
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.
Trade group also compiled website with information and resources to help members "stay up to date and take any necessary steps to mitigate the risks associated with COVID-19." Its members also got a chance to describe potential supply chain disruptions in survey for USDA.